ChemGenex Pharmaceuticals Limited
1 Pigdon's Road
Waurn Pond
Victoria
3217
Tel: 61-3-5227-2752
Fax: 61-3-5227-1322
Website: http://www.chemgenex.com/
Email: info@chemgenex.com
About ChemGenex Pharmaceuticals Limited
ChemGenex Pharmaceuticals is a gene-based pharmaceutical development company dedicated to improving the lives of patients by developing novel protein, antibody and small molecule therapeutics in the areas of oncology, obesity, diabetes and central nervous system disorders. The company was formed in 2004 from the merger of AGT Biosciences of Melbourne, Australia and privately held ChemGenex Therapeutics, Inc. of Menlo Park, California.The ChemGenex pipeline of therapeutics is based on internally discovered targets that play a role in important mechanisms underlying metabolic and CNS diseases coupled with later-stage small molecules in clinical development for the treatment of cancer. The company uses genomic tools such as patient genotyping in clinical development to reduce clinical risk and improve patient outcomes.
ChemGenex has assembled a comprehensive technology platform that combines novel disease models with robust human genetics to identify novel targets. These discoveries are then validated with a range of systems biology approaches and evaluated in terms of drugability. The company's target discovery and validation approach is based on:
ChemGenex has identified genes whose protein products have potential as suitable therapeutics, have disease associations and are protected by an intellectual property position. Using animal models in both diabetes and obesity the company is currently evaluating the activity of proteins and small molecules as potential human therapeutics in conjunction with Merck KGaA. ChemGenex is also collaborating with Vernalis in the areas of anxiety and depression.
Date Established: 2004 (formed by a merger)
Other Company Location:
3475 Edison Way, Suite M Menlo Park, California 94025 U.S.A. Phone: 650-474-9800 Fax: 650-474-9808
Last Updated: 11-09-04
82 articles about ChemGenex Pharmaceuticals Limited
-
Cephalon, Inc. Lodges Bidder's Statement for A$167 Million Offer for ChemGenex Pharmaceuticals Limited
4/13/2011
-
Cephalon, Inc. Offers To Buy Rest Of Australia's ChemGenex Pharmaceuticals Limited For $163M
3/29/2011
-
ChemGenex Pharmaceuticals Limited Presents Updated Analysis at American Society of Hematology on OMAPRO(TM) in CML Patients Who Failed Two or Three Approved TKI Drugs
12/6/2010
-
LifeSci Advisors, LLC (LSA) Announces Investment Opinion on ChemGenex Pharmaceuticals Limited
10/7/2010
-
ChemGenex Pharmaceuticals Limited Completes pre-NDA Meeting with U.S. FDA and Clarifies Timing for Second New Drug Application for OMAPROTM
10/5/2010
-
ChemGenex Pharmaceuticals Limited and U.S. FDA Agree on Potential Regulatory Pathway for OMAPRO(TM)
7/14/2010
-
ChemGenex Pharmaceuticals Limited Announces Positive Safety Data on OMAPR(TM) Presented at American Society of Clinical Oncology
6/7/2010
-
ChemGenex Pharmaceuticals Limited to Host Investor Briefing
5/4/2010
-
ChemGenex Pharmaceuticals Limited Receives a Complete Response Letter from the FDA for OMAPRO(TM)
4/12/2010
-
FDA's Oncologic Drug Advisory Committee Recommends ChemGenex Pharmaceuticals Limited Validate a Diagnostic Prior to Approval of OMAPRO in Chronic Myeloid Leukemia Patients with T315I Mutation
3/23/2010
-
U.S. FDA Sets 22 March for Oncologic Drugs Advisory Committee (ODAC) Meeting to Review ChemGenex Pharmaceuticals Limited's OMAPRO(TM)
3/2/2010
-
ChemGenex Pharmaceuticals Limited: Extreme Weather in Washington D.C. has Postponed the FDA's Oncologic Drugs Advisory Committee Meeting Scheduled for 10 February 2010
2/9/2010
-
Beckman Coulter, Inc. To Distribute CompuCyte Corporation Laser Scanning Cytometers
12/14/2009
-
Pivotal Data on ChemGenex Pharmaceuticals Limited's Omapro(TM) Highlighted at American Society of Hematology Press Conference
12/7/2009
-
ChemGenex Pharmaceuticals Limited to Present Positive Data for Omapro(TM) From Multiple Clinical Trials at American Society of Hematology
12/1/2009
-
ChemGenex Pharmaceuticals Limited's Marketing Authorization Application for Omacetaxine Mepesuccinate Validated by the European Medicines Evaluation Agency
11/30/2009
-
ChemGenex Pharmaceuticals Limited Announces FDA Accepts NDA for Omapro(TM) (Omacetaxine Mepesuccinate) and Grants the Filing Priority Review Status
11/11/2009
-
ChemGenex Pharmaceuticals Limited Submits New Drug Application for OMAPRO(TM) (Omacetaxine Mepesuccinate) to U.S. FDA
9/9/2009
-
ChemGenex Pharmaceuticals Limited's Omacetaxine Kills Leukemic Stem Cells in Human CML Models
6/8/2009
-
Pivotal Study Results: ChemGenex Pharmaceuticals Limited's Omacetaxine May Provide the First Viable Drug Treatment Option for Patients With a Highly Resistant Form of CML
6/1/2009